<DOC>
	<DOCNO>NCT00423488</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled study ass , 6 week dose , whether co-administration ezetimibe 10 mg simvastatin 20 mg effective treatment double dose simvastatin 40 mg alone reduce low-density lipoprotein-cholesterol ( LDL-C ) concentration achieve National Cholesterol Expert Panel ( NCEP ) III LDL-C target goal &lt; 2.6 mmol/L ( &lt; 100 mg/dL ) subject diabetes mellitus coronary heart disease .</brief_summary>
	<brief_title>Ezetimibe Simvastatin Primary Hypercholesterolemia , Diabetes Mellitus Type 2 , Coronary Heart Disease ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Subject must diabetes mellitus type 2 ( fast plasma glucose &gt; 7 mmol/L [ 126 mg/dL ] ) least 12 month duration Visit 3 must adequately control ( glycated hemoglobin [ HbA1c ] &lt; =9.0 % ) . Subjects must change antidiabetic pharmacotherapy [ i.e . change dosage ( exception +/ 10 unit insulin ) addition new medication ] experience recent history repeat hypoglycemia unstable glycemic control within 3 month Visit ( Baseline Visit ) . Subjects must document coronary heart disease ( CHD ) . For purpose study , CHD include one follow feature : document stable angina evidence ischemia exercise test ) ; history myocardial infarction ; history percutaneous transluminal coronary intervention ( PCTI ) without stent placement ) ; symptomatic peripheral vascular disease ( claudication ) ; document history atherothrombotic cerebrovascular disease ; and/or document history unstable angina nonQ wave myocardial infarction . Subjects must lowdensity lipoprotein cholesterol ( LDLC ) concentration &gt; =2.6 mmol/L ( 100 mg/dL ) &lt; =4.1 mmol/L ( 160 mg/dL ) use Friedewald calculation available time randomization Visit 3 ( Baseline Visit ) . Subjects must triglyceride concentration &lt; 3.99 mmol/L ( 350 mg/dL ) Visit 3 ( Baseline Visit ) . Subject must currently take simvastatin 20 mg daily history take 80 % daily evening dose 6 week prior Visit 3 ( Baseline Visit ) . Subject must &gt; =18 year &lt; =75 year age . Subjects must maintain cholesterol lower diet exercise program least 4 week prior Screening ( Visit 2 ) willing continue diet exercise program study . Subjects must liver transaminase ( alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] ) &lt; 50 % upper limit normal , active liver disease , creatinine kinase ( CK ) &lt; 50 % upper limit normal Visit 3 ( Baseline Visit ) . Clinical laboratory test ( complete blood count ( CBC ) , blood chemistry , urinalysis ) must within normal limit clinically acceptable investigator Visit 3 ( Baseline Visit ) . Subjects must report stable weight history least 4 week prior entry study Visit 3 ( Baseline Visit ) . Women receive hormonal therapy , include hormone replacement , estrogen antagonist/agonist , oral contraceptive , must maintain stable dose regimen least 8 week willing continue regimen duration study . Women childbearing potential ( include woman less 1 year postmenopausal woman become sexually active ) must use acceptable method birth control ( e.g. , hormonal contraceptive , medicallyprescribed intrauterine device ( IUD ) , condom combination spermicide ) surgically sterilize ( e.g. , hysterectomy tubal ligation ) . Subjects must free clinically significant disease diabetes mellitus coronary heart disease would interfere study evaluation . Subjects must understand able adhere dose visit schedule , must agree remain cholesterollowering diet exercise regimen duration study Subjects must demonstrate willingness participate study comply procedure sign write informed consent . Subjects whose body mass index ( BMI = weight [ kg ] /height [ ] **2 ) &gt; =35 kg/m**2 Visit 3 ( Baseline Visit ) . Subjects consume &gt; 14 alcoholic drink per week . ( A drink : beer , glass wine , single measure spirit ) . Any condition situation , opinion investigator , might pose risk subject interfere participation study . Women pregnant nursing . Congestive heart failure define New York Heart Association ( NYHA ) Class III IV . Uncontrolled cardiac arrhythmia . Myocardial infarction , acute coronary insufficiency , coronary artery bypass surgery , angioplasty within 3 month Visit 3 ( Baseline Visit ) . Unstable severe peripheral artery disease within 3 month Visit 3 ( Baseline Visit ) . Newly diagnose currently unstable angina pectoris . Uncontrolled hypertension ( treat untreated ) systolic blood pressure &gt; 160 mmHg diastolic &gt; 100 mmHg Visit 3 ( Baseline Visit ) . Uncontrolled endocrine metabolic disease know influence serum lipid lipoprotein , i.e. , secondary cause hyperlipidemia , secondary hypercholesterolemia due hypothyroidism ( thyroid stimulate hormone [ TSH ] upper limit normal ) Visit 3 . Subjects history hypothyroidism stable therapy thyroid hormone replacement least 6 week eligible enrollment TSH level within normal limit Visit 3 ( Baseline Visit ) . Impaired renal function ( creatinine &gt; 2.0 mg/dL ) nephrotic syndrome Visit 3 ( Baseline Visit ) . Disorders hematologic , digestive , central nervous system include cerebrovascular disease degenerative disease would limit study evaluation participation . Known human immunodeficiency virus ( HIV ) positive . Cancer within past 5 year ( except successfully treat basal squamous cell carcinoma ) . History mental instability , drug/alcohol abuse within past 5 year , major psychiatric illness adequately control stable pharmacotherapy . Subjects observed designate washout period prohibit medication . Subjects currently consume large amount grapefruit juice ( &gt; 1 liter/day ) . Oral corticosteroid , unless use replacement therapy pituitary/adrenal disease subject stable regimen l 6 week prior Visit 3 ( Baseline Visit ) . Subjects currently use cardiovascular medication ( e.g. , antihypertensive , antiarrhythmic ) stable regimen least 6 week prior Visit 3 ( Baseline Visit ) expect change study . Subjects currently use psyllium , fiberbased laxative , and/or overthecounter ( OTC ) therapy know affect serum lipid level ( phytosterol margarine ) , stable regimen least 5 week prior study entry Visit 3 ( Baseline Visit ) agree remain regimen throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>